C2N Diagnostics has partnered with LSI Medience to pursue regulatory approval and commercialization of the PrecivityAD2 blood test in Japan, following the assay's recent FDA clearance in the United States. The test measures plasma biomarkers associated with amyloid pathology, offering a less invasive alternative to PET imaging and cerebrospinal fluid analysis for Alzheimer's assessment. Expansion into Japan targets one of the world's oldest populations, where dementia prevalence and diagnostic demand are among the highest globally.
Key Points
- PrecivityAD2 blood test targets Japanese market after US FDA clearance
- Plasma biomarker testing bypasses PET imaging and lumbar puncture
- Japan's aging demographics drive high demand for earlier dementia diagnosis
Longevity Analysis
Accessible blood-based detection of amyloid pathology shifts Alzheimer's assessment from specialist settings into routine clinical practice, enabling identification of disease processes years before functional decline. Earlier stratification matters increasingly as anti-amyloid therapies require treatment during the window when neuronal loss remains limited. Japan's demographic profile makes it a practical test case for whether population-scale cognitive screening can be operationalized within existing health systems.
Original published by LT Wire.